The process development of oral solid dosage forms occurs across multiple phases. The final scaled up process is not typically finalized until shortly before filing for commercial approval. Continuous manufacturing is well suited for phase III development and clinical manufacturing and enables late-phase development by ensuring a greater quality assurance and reducing API usage. Additionally, continuous manufacturing doesn’t require scale up and expedites readiness from phase III to commercial.
Download this on-demand webinar, to hear industry expert, Doug Hausner discuss: